Predictive Oncology (NASDAQ: POAI)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-10 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.050 | ||||||
REV | 314.568K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Predictive Oncology (NASDAQ: POAI) through any online brokerage.
Other companies in Predictive Oncology’s space includes: RxSight (NASDAQ:RXST), TELA Bio (NASDAQ:TELA), Chembio Diagnostics (NASDAQ:CEMI), Meihua International (NASDAQ:MHUA) and InspireMD (NASDAQ:NSPR).
The latest price target for Predictive Oncology (NASDAQ: POAI) was reported by HC Wainwright & Co. on Wednesday, June 30, 2021. The analyst firm set a price target for 5.00 expecting POAI to rise to within 12 months (a possible 1355.18% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Predictive Oncology (NASDAQ: POAI) is $0.3436 last updated May 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Predictive Oncology.
Predictive Oncology’s Q2 earnings are confirmed for Wednesday, August 10, 2022.
There is no upcoming split for Predictive Oncology.
Predictive Oncology is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.